AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline - Candlesense
ABBV Mergers

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser. NORTH...

Related Questions

How will the acquisition of bretisilocin affect AbbVie's short‑term and long‑term earnings outlook? What is the anticipated timeline for FDA approval and market rollout of bretisilocin, and how might that influence the stock price? How does bretisilocin’s potential market size and competitive positioning compare to existing antidepressants and other emerging psychedelic therapies?
Find similar articles on Candlesense prnewswire